Accordingly, CAMK2N1 was not only described as tumor suppressor in EOC by our group but in multiple myeloma, oral squamous cell carcinoma, prostate cancer and thyroid cancer throughout the last years [75–78]. Here, CAMK2N1 is linked to thyroid gland carcinoma.